Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

UroGen Pharma Q3 2026 Results: Net Loss of $1.46M, Loss Narrows

UroGen Pharma Ltd. reported Q3 2026 results featuring revenue from Jelmyto and Zusduri. The company significantly restructured its debt in early 2026, including a $100 million loan agreement with Pharmakon and the classification of $11.2 million in prepaid forward obligations as current liabilities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue89.027.5
Gross profit81.524.2
Profit before tax-0.4-34.4
Net income-1.5-33.3
EPS (diluted, $ a share)$-0.03$-0.69

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+223.9%
Gross margin91.6%
Operating margin9.4%
Source

10-Q filed with the SEC, NASDAQ: URGN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

UroGen Pharma Ltd.: key numbers

Share price
$28.10Close, Nov 16
Market cap
$1.38B
Shares outstanding
49.05MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from UroGen Pharma Ltd.

All →
8:08 AM ET 8-K
Financial Results

UroGen Pharma Financial Results

UroGen Pharma reported third-quarter 2026 financial results, highlighted by $68.0 million in ZUSDURI revenue, representing 35% sequential growth. The company also announced that the FDA has accepted its NDA for UGN-103 with a PDUFA goal date of June 14, 2027, and reported a cash position of $215.4 million.

“We delivered another strong quarter of execution, with ZUSDURI continuing to scale as growing repeat utilization, expanding community adoption, and broader physician engagement reinforce our confidence in the long-term commercial opportunity.”

Liz Barrett, President and Chief Executive Officer of UroGen

“The U.S. Food and Drug Administration’s (FDA’s) acceptance of the UGN-103 New Drug Application (NDA) in low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), together with our newly issued patent providing coverage into July 2044, further reinforce the long-term revenue potential of our bladder cancer portfolio.”

Liz Barrett, President and Chief Executive Officer of UroGen
12:57 PM ET Form 4
Insider Selling

UroGen Pharma CFO Chris Degnan Sells $80.8K of Stock

Chris Degnan, CFO, sold 2,202 shares of UroGen Pharma Ltd. at $36.69 a share, worth $80.8K in total on Oct 8, 2026. Shares held after the trade: 4,561 (-32.6%).

Value
$80.8K
Shares
2,202
Price
$36.69
Role
CFO
Holding change
-32.6%
Trade date
Oct 8, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.